Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267876 · ClinicalTrials.gov registry record
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
A clinical trial of Human Papilloma Virus and Cervical Neoplasms, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 6,730
- Enrollment target
- 20
- Study locations
NCT02267876: Completed study of Human Papilloma Virus and Cervical Neoplasms, sponsored by Becton, Dickinson and Company.
NCT02267876 is a study of Human Papilloma Virus and Cervical Neoplasms that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 6,730 participants, below the 8,269-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267876, a study of Human Papilloma Virus and Cervical Neoplasms, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 6,730 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the cumulative disease detection of greater than or equal to Cervical intraepithelial neoplasia 2 (CIN2) and greater than or equal to Cervical intraepithelial neoplasia 3 (CIN3) in the subjects over 3 years using the subject's HPV status and cytology status from the BDS-USHPV baseline results
Primary Outcome
Cumulative risk is a measure of the total risk that a certain event will happen during a given period of time. In this longitudinal study, it refers to the risk of developing \>=CIN2 or \>=CIN3 in subjects over a three year period using the subjects' HPV status at baseline versus cytology status at baseline.
Conditions Studied
Interventions
- PROCEDURE Colposcopy
- DEVICE BD HPV Assay on Viper LT
Study Locations (20)
Florida
- Health Awareness Inc. - Jupiter
- Altus Research - Lake Worth
- Segal Institute for Clinical Research - North Miami
- Miami Research Associates - South Miami
- Comprehensive Clinical Trails, LLC - West Palm Beach
Arizona
- Women's Health Research of Arizona - Phoenix
- Quality of Life Medical & Research Center - Tucson
- Visions Clinical Research - Tucson
Alabama
- University of Alabama - Birmingham
- Mobile OB/GYN - Mobile
Georgia
- Medical Network for Education & Research - Decatur
- Fellows Research Alliance - Savannah - Savannah
California
- Women's Health Care Research Corp. - San Diego
Colorado
- Blueskies Center for Women - Colorado Springs
Illinois
- Women's Health Practice - Champaign
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,730 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-05 |
What the finished NCT02267876 record still lists
NCT02267876 is an observational study that tracks outcomes without assigning an intervention. Its 6,730 participants enrollment target places it among the larger protocols in the corpus, below the 8,269-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 2 interventions - of which Colposcopy is the first listed.
NCT02267876 names 20 study sites across 12 states, led by Florida, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02267876 about?
NCT02267876 is a clinical study titled "Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens". The purpose of the study is to assess the cumulative disease detection of greater than or equal to Cervical intraepithelial neoplasia 2 (CIN2) and greater than or equal to Cervical intraepithelial neoplasia 3 (CIN3) in the subjects over 3 years using the subject's HPV status and cytology status from...
What is the current status of trial NCT02267876?
This trial is currently completed. The enrollment target is 6,730 participants. The study started on 2014-10. Estimated completion is 2019-05.
What conditions does trial NCT02267876 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Cervical Neoplasms.
What interventions are being tested in trial NCT02267876?
The interventions under investigation include: Colposcopy (PROCEDURE), BD HPV Assay on Viper LT (DEVICE).
Who is sponsoring clinical trial NCT02267876?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267876 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02267876's enrollment target sits among peer trials
6,730 2nd of 39 the highest of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05121324 · 6,700 participants · Phase 3
Pediatric Dose Optimization for Seizures in Emergency Medical Services
- NCT03887715 · 6,800 participants · NA
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- NCT06234384 · 6,833 participants
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia